Programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) is accepted as a predictive biomarker for the selection of immune checkpoint inhibitors. We evaluated the staining quality and estimation of the tumor proportion score (TPS) in non-small-cell lung cancer during two external quality assessment (EQA) schemes by the European Society of Pathology. Participants received two tissue micro-arrays with three (2017) and four (2018) cases for PD-L1 IHC and a positive tonsil control, for staining by their routine protocol. After the participants returned stained slides to the EQA coordination center, three pathologists assessed each slide and awarded an expert staining score from 1 to 5 points based on the staining concordance. Expert scores significantly (p < 0.01) improved between EQA schemes from 3.8 (n = 67) to 4.3 (n = 74) on 5 points. Participants used 32 different protocols: the majority applied the 22C3 (56.7%) (Dako), SP263 (19.1%) (Ventana), and E1L3N (Cell Signaling) (7.1%) clones. Staining artifacts consisted mainly of very weak or weak antigen demonstration (63.0%) or excessive background staining (19.8%). Participants using CE-IVD kits reached a higher score compared with those using laboratory-developed tests (LDTs) (p < 0.05), mainly attributed to a better concordance of SP263. The TPS was under- and over-estimated in 20/423 (4.7%) and 24/423 (5.7%) cases, respectively, correlating to a lower expert score. Additional research is needed on the concordance of less common protocols, and on reasons for lower LDT concordance. Laboratories should carefully validate all test methods and regularly verify their performance. EQA participation should focus on both staining concordance and interpretation of PD-L1 IHC.

Center for Oncologic Research University of Antwerp Antwerp Belgium

Department of Pathology Charles University Medical Faculty and University Hospital Hradec Kralove Czech Republic

Department of Pathology Isala Klinieken Zwolle The Netherlands

Department of Pathology University Hospital Antwerp Edegem Belgium

Department of Pathology University Medical Center Groningen Groningen The Netherlands

Department of Pathology University Medical Center Rotterdam Erasmus MC Rotterdam The Netherlands

Department of Public Health and Primary Care Biomedical Quality Assurance Research Unit University of Leuven Leuven Belgium

Zobrazit více v PubMed

Food and Drug Administration (2019) Nivolumab prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf. Accessed 30 Mar 2020

European Medicines Agency (2019) Opdivo European public assessment report. https://www.ema.europa.eu/en/documents/overview/opdivo-epar-medicine-overview_en.pdf. Accessed 30 Mar 2020

Food and Drug Administration (2020) Pembrolizumab prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s066lbl.pdf. Accessed 30 Mar 2020

European Medicines Agency (2019) Keytruda European public assessment report. https://www.ema.europa.eu/en/documents/overview/keytruda-epar-medicine-overview_en.pdf. Accessed 30 Mar 2020

Food and Drug Administration (2019) Atezolizumab prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761034s018lbl.pdf. Accessed 30 Mar 2020

European Medicines Agency (2019) Tecentriq European public assessment report. https://www.ema.europa.eu/en/documents/overview/tecentriq-epar-medicine-overview_en.pdf. Accessed 30 Mar 2020

Ellis PM, Vella ET, Ung YC (2017) Immune checkpoint inhibitors for patients with advanced non-small-cell lung cancer: a systematic review. Clin Lung Cancer 18(5):444–459.e1. 10.1016/j.cllc.2017.02.001 PubMed

Peng M, Li X, Lei G, Weng YM, Hu MX, Song QB. The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis. Onco Targets Ther. 2018;11:7369–7383. doi: 10.2147/OTT.S177318. PubMed DOI PMC

Food and Drug Administration (2020) https://www.accessdata.fda.gov. Accessed 30 Mar 2020

European Medicines Agency (2020) https://www.ema.europa.eu. Accessed 30 Mar 2020

Food and Drug Administration, Durvalumab prescribing information (2018) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761069s002lbl.pdf. Accessed 30 Mar 2020

European Medicines Agency (2018) Imfinzi public assessment report. https://www.ema.europa.eu/en/documents/overview/imfizi-epar-medicine-overview_en.pdf. Accessed 30 Mar 2020

European Counsil Directive (2004) The European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells. 2004/23/EC.

Food and Drug Administration (2020) List of cleared or approved companion diagnostic devices (in vitro and imaging tools). https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools. Accessed 30 March 2020

Teixidó C, Vilariño N, Reyes R, Reguart N. PD-L1 expression testing in non-small cell lung cancer. Ther Adv Med Oncol. 2018;10:1758835918763493. doi: 10.1177/1758835918763493. PubMed DOI PMC

Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, Rüschoff J, Schildhaus HU, Schirmacher P, Tiemann M, Warth A, Weichert W, Fischer RN, Wolf J, Buettner R. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol. 2016;29(10):1165–1172. doi: 10.1038/modpathol.2016.117. PubMed DOI

Büttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, Dietel M, Longshore JW, López-Ríos F, Penault-Llorca F, Viale G, Wotherspoon AC, Kerr KM, Tsao MS. Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer. J Clin Oncol. 2017;35(34):3867–3876. doi: 10.1200/JCO.2017.74.7642. PubMed DOI

Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, Richardson W, Towne P, Hanks D, Vennapusa B, Mistry A, Kalamegham R, Averbuch S, Novotny J, Rubin E, Emancipator K, McCaffery I, Williams JA, Walker J, Longshore J, Tsao MS, Kerr KM. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol. 2017;12(2):208–222. doi: 10.1016/j.jtho.2016.11.2228. PubMed DOI

Ratcliffe MJ, Sharpe A, Midha A, Barker C, Scott M, Scorer P, Al-Masri H, Rebelatto MC, Walker J. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer. Clin Cancer Res. 2017;23(14):3585–3591. doi: 10.1158/1078-0432.CCR-16-2375. PubMed DOI

Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba II. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol. 2017;3(8):1051–1058. doi: 10.1001/jamaoncol.2017.0013. PubMed DOI PMC

Adam J, Le Stang N, Rouquette I, Cazes A, Badoual C, Pinot-Roussel H, Tixier L, Danel C, Damiola F, Damotte D, Penault-Llorca F, Lantuéjoul S. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Ann Oncol. 2018;29(4):953–958. doi: 10.1093/annonc/mdy014. PubMed DOI

Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou TY, Chung JH, Dacic S, Lantuejoul S, Mino-Kenudson M, Moreira AL, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Russell PA, Sauter J, Thunnissen E, Wistuba I, Yu H, Wynes MW, Pintilie M, Yatabe Y, Hirsch FR. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol. 2018;13(9):1302–1311. doi: 10.1016/j.jtho.2018.05.013. PubMed DOI PMC

Lantuejoul S, Damotte D, Hofman V, Adam J (2019) Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma. J Thorac Dis 11(Suppl 1):S89–S101. 10.21037/jtd.2018.12.103 PubMed PMC

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142(3):321–346. doi: 10.5858/arpa.2017-0388-CP. PubMed DOI

Fitzgibbons PL, Goldsmith JD, Souers RJ, Fatheree LA, Volmar KE, Stuart LN, Nowak JA, Astles JR, Nakhleh RE. Analytic validation of immunohistochemical assays: a comparison of laboratory practices before and after introduction of an evidence-based guideline. Arch Pathol Lab Med. 2017;141(9):1247–1254. doi: 10.5858/arpa.2016-0558-CP. PubMed DOI PMC

International Organization for Standardization . ISO 15189:2012 Medical laboratories - Particular requirements for quality and competence. Geneva: ISO; 2012.

Pagliuso J. The challenges of implementing a PD-L1 proficiency testing program and RCPAQAP update. Pathology. 2018;50(Suppl1):S7. doi: 10.1016/j.pathol.2017.12.012. DOI

Dodson A, Parry S, Lissenberg-Witte B, Haragan A, Allen D, O'Grady A, McClean E, Hughes J, Miller K, Thunnissen E. External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different. J Pathol Clin Res. 2019;6:138–145. doi: 10.1002/cjp2.153. PubMed DOI PMC

Nordic Immunohistochemical Quality Control (2019) PD-L1 Run C5. https://www.nordiqc.org/downloads/assessments/121_102.pdf.

Tack V, Schuuring E, Keppens C, Hart N’, Pauwels P, van Krieken H, Dequeker EMC. Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratories. Br J Cancer. 2018;119(5):605–614. doi: 10.1038/s41416-018-0204-9. PubMed DOI PMC

International Organization for Standardisation . ISO/IEC 17043:2010 Conformity assessment - general requirements for proficiency testing. Geneva: ISO; 2010.

Gaule P, Smithy JW, Toki M, Rehman J, Patell-Socha F, Cougot D, Collin P, Morrill P, Neumeister V, Rimm DL. A quantitative comparison of antibodies to programmed cell death 1 ligand 1. JAMA Oncol. 2017;3(2):256–259. doi: 10.1001/jamaoncol.2016.3015. PubMed DOI PMC

Tsao MSKK, Dacic S, Yatabe Y, Hirsch FR. IASLC atlas of PD-L1 immunohistochemistry testing in lung cancer. International Association for the Study of Lung Cancer: Editorial Rx Press; 2017.

Lin F, Chen Z. Standardization of diagnostic immunohistochemistry: literature review and geisinger experience. Arch Pathol Lab Med. 2014;138(12):1564–1577. doi: 10.5858/arpa.2014-0074-RA. PubMed DOI

Ibrahim M, Parry S, Wilkinson D, Bilbe N, Allen D, Forrest S, Maxwell P, O'Grady A, Starczynski J, Tanier P, Gosney J, Kerr K, Miller K, Thunnissen E. ALK immunohistochemistry in NSCLC: discordant staining can impact patient treatment regimen. J Thorac Oncol. 2016;11(12):2241–2247. doi: 10.1016/j.jtho.2016.07.012. PubMed DOI

Keppens C, von der Thüsen JH, Pauwels P, Ryska A, ’tHart N, Schuuring E, Miller K, Thunnissen E, Zwaenepoel K, Dequeker EMC. Staining performance of ALK and ROS1 immunohistochemistry and influence on interpretation in NSCLC. 2020. PubMed

Munari E, Zamboni G, Lunardi G, Marconi M, Brunelli M, Martignoni G, Netto GJ, Quatrini L, Vacca P, Moretta L, Bogina G. PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays. Hum Pathol. 2019;90:54–59. doi: 10.1016/j.humpath.2019.05.003. PubMed DOI

Richards KL (2019) Complying With the new EU IVDR. https://www.precisionmedicinegrp.com/pfm/wp-content/uploads/sites/3/2018/09/Complying-With-the-new-EU-IVDR-Regulatory-Focus-2018-08.pdf.

Munari E, Rossi G, Zamboni G, Lunardi G, Marconi M, Sommaggio M, Netto GJ, Hoque MO, Brunelli M, Martignoni G, Haffner MC, Moretta F, Pegoraro MC, Cavazza A, Samogin G, Furlan V, Mariotti FR, Vacca P, Moretta L, Bogina G. PD-L1 assays 22C3 and SP263 are not interchangeable in non-small cell lung cancer when considering clinically relevant cutoffs: an interclone evaluation by differently trained pathologists. Am J Surg Pathol. 2018;42(10):1384–1389. doi: 10.1097/PAS.0000000000001105. PubMed DOI

Prinsen CF, Klaassen CH, Thunnissen FB. Microarray as a model for quantitative visualization chemistry. Appl Immunohistochem Mol Morphol. 2003;11(2):168–173. doi: 10.1097/00129039-200306000-00014. PubMed DOI

Botti G, Scognamiglio G, Cantile M. PD-L1 immunohistochemical detection in tumor cells and tumor microenvironment: main considerations on the use of tissue micro arrays. Int J Mol Sci. 2016;17(7):1046. doi: 10.3390/ijms17071046. PubMed DOI PMC

Keppens C, Tack V, ‘t Hart N, Tembuyser L, Ryska A, Pauwels P, Zwaenepoel K, Schuuring E, Cabillic F, Tornillo L, Warth A, Weichert W, Dequeker E, EQA assessors expert group (2018) A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer. Oncotarget 9(29):20524-20538. 10.18632/oncotarget.24980 PubMed PMC

Torlakovic EE, Nielsen S, Francis G, Garratt J, Gilks B, Goldsmith JD, Hornick JL, Hyjek E, Ibrahim M, Miller K, Petcu E, Swanson PE, Zhou X, Taylor CR, Vyberg M. Standardization of positive controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Committee. Appl Immunohistochem Mol Morphol. 2015;23(1):1–18. doi: 10.1097/PAI.0000000000000163. PubMed DOI

Torlakovic EE, Cheung CC, D'Arrigo C, Dietel M, Francis GD, Gilks CB, Hall JA, Hornick JL, Ibrahim M, Marchetti A, Miller K, van Krieken JH, Nielsen S, Swanson PE, Vyberg M, Zhou X, Taylor CR, From the International Society for Immunohistochemistry and Molecular Morphology (ISIMM) and International Quality Network for Pathology (IQN Path) Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine—part 2: immunohistochemistry test performance characteristics. Appl Immunohistochem Mol Morphol. 2017;25(2):79–85. doi: 10.1097/PAI.0000000000000444. PubMed DOI